REBYOTA® (fecal microbiota, live-jslm) is an FDA-approved microbiota-based therapy designed to prevent recurrent Clostridioides difficile infection (rCDI). The PUNCH CD3-OLS trial explored its safety and efficacy in patients with both rCDI and irritable bowel syndrome (IBS), a population often excluded from rCDI studies due to overlapping symptoms like diarrhea and abdominal pain.
REBYOTA® (fecal microbiota, live-jslm) is an FDA-approved microbiota-based therapy designed to prevent recurrent Clostridioides difficile infection (rCDI). The PUNCH CD3-OLS trial explored its safety and efficacy in patients with both rCDI and irritable bowel syndrome (IBS), a population often excluded from rCDI studies due to overlapping symptoms like diarrhea and abdominal pain. IBS is linked to gut microbiome imbalances, making microbiota restoration with REBYOTA® a promising therapeutic approach.
The study involved 697 participants, 90 of whom had IBS. Patients received a single rectal dose of REBYOTA® after completing standard antibiotic treatment for CDI. IBS participants had high rates of prior CDI episodes (70% had ≥3 episodes), highlighting their complex medical history. Despite this, REBYOTA® demonstrated robust efficacy: 68.9% of IBS patients achieved treatment success at 8 weeks, defined as the absence of CDI diarrhea, and 82.3% maintained remission for 6 months.
Safety outcomes were favorable, with most treatment-emergent adverse events (TEAEs) being mild or moderate. IBS patients reported slightly higher gastrointestinal TEAEs (e.g., diarrhea, nausea), likely reflecting baseline IBS symptoms rather than treatment complications. Serious adverse events were rare and unrelated to REBYOTA®.
REBYOTA® effectively restored microbial diversity, reducing CDI recurrence risk and addressing microbiota-related IBS vulnerabilities. While the trial was open-label and lacked IBS subtype data, findings support expanding microbiota-based therapies to complex populations like IBS patients with rCDI. REBYOTA® offers a safe, well-tolerated, and effective option for improving outcomes in these challenging cases.
This review redefines dopamine (DA) signaling beyond its classical role in reward processing, positioning dopaminergic circuits as central regulators of feeding behavior, metabolic sensing, and energy homeostasis. The authors describe how distributed dopamine ensembles across...
Introduction Atherosclerosis has traditionally been viewed as a lipid-driven disease. However, emerging evidence highlights a critical role of chronic inflammation and immune activation, with the gut microbiota now recognised as a key modulator of vascular...
Clinical Summary In this randomized international trial (COBRRA), investigators compared the bleeding risk of apixaban vs. rivaroxaban in patients with acute venous thromboembolism (VTE), including pulmonary embolism and proximal deep-vein thrombosis. A total of 2,760...
The American College of Gastroenterology (ACG) 2025 meeting is a prominent annual event where groundbreaking research, clinical studies, and advancements in gastroenterology are presented. At the ACG 2025 meeting, several impactful studies were showcased, providing...
Alcohol Use Disorder (AUD) and Alcohol-Related Liver Disease (ArLD) often coexist, presenting a complex clinical challenge that requires careful consideration of pharmacological treatment. Below is a detailed explanation starting from definitions, the need for pharmacological...
Copper dysregulation plays a central role in the pathogenesis of Wilson disease (WD). The disease arises from the body’s inability to regulate copper levels, leading to its accumulation and subsequent toxicity. Below is a detailed...
We are pioneers in clinical intelligence, dedicated to helping gastroenterologists harness the power of artificial intelligence to drive precision, efficiency, and patient growth.